Helus Pharma Adds Pfizer Veteran to Board, Strengthening Scientific Leadership — Cybin Inc.

Event summary

Helus Pharma appoints Dr. Freda Lewis-Hall, former Pfizer Chief Medical Officer, to its Board of Directors and as Chair of the Scientific Advisory Committee.
Dr. Lewis-Hall brings over 40 years of experience in clinical care, research, and biopharmaceutical leadership, including roles at Pfizer, Vertex, and Bristol Myers Squibb.
She previously helped lead the spinout of SpringWorks Therapeutics, which was acquired by Merck KGaA for approximately $3.4 billion.
Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (NSA) portfolio.
Appointment is subject to approval of Cboe Canada.

The big picture

Helus Pharma’s appointment of Dr. Freda Lewis-Hall signals a strategic move to bolster its scientific and regulatory capabilities, critical for advancing its NSA portfolio in the competitive mental health space. Her track record in guiding complex therapies from development to commercialization, including her role in SpringWorks’ $3.4 billion acquisition, underscores the company’s focus on disciplined execution and patient-centric innovation. This appointment comes as Helus aims to differentiate itself in the treatment of serious mental health conditions, leveraging her deep industry experience to navigate regulatory hurdles and enhance clinical outcomes.

What we're watching

Scientific Rigor: How Dr. Lewis-Hall’s emphasis on clinical design and regulatory clarity will impact Helus’ pipeline advancement.
Regulatory Pathways: Whether her experience can accelerate approvals for Helus’ NSA programs, particularly HLP003 and HLP004.
Market Recognition: The pace at which the broader market acknowledges Helus’ differentiated development platform under her leadership.